Crossref
Immunotherapy unleashed: pioneering chemo-free neoadjuvant programmed cell death ligand 1 (PD-L1) inhibition for resectable non-small cell lung cancer (NSCLC)
AME Clinical Trials Review · 2024
DOI: 10.21037/actr-23-34 ↗Kurz gefasst
Fachartikel in der Zeitschrift AME Clinical Trials Review, 2024. Verfasst von Nikki E. Rossetti und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Rossetti, N. E., & Puri, V. (2024). Immunotherapy unleashed: pioneering chemo-free neoadjuvant programmed cell death ligand 1 (PD-L1) inhibition for resectable non-small cell lung cancer (NSCLC). AME Clinical Trials Review. https://doi.org/10.21037/actr-23-34
Vancouver
Rossetti NE, Puri V. Immunotherapy unleashed: pioneering chemo-free neoadjuvant programmed cell death ligand 1 (PD-L1) inhibition for resectable non-small cell lung cancer (NSCLC). AME Clinical Trials Review. 2024. doi:10.21037/actr-23-34
BibTeX
@article{Rossetti2024,
author = {Rossetti, Nikki E. and Puri, Varun},
title = {Immunotherapy unleashed: pioneering chemo-free neoadjuvant programmed cell death ligand 1 (PD-L1) inhibition for resectable non-small cell lung cancer (NSCLC)},
journal = {AME Clinical Trials Review},
year = {2024},
doi = {10.21037/actr-23-34}
}
EUVIMED